

SYNTHESIS of (4R)-4-((E)-2-BUTENYL)-4,N-DIMETHYL-L-THREONINE (MeBMT),
THE CHARACTERISTIC AMINO ACID OF CYCLOSPORINE¹


Ulrich Schmidt* and Wolfgang Siegel

Institut für Organische Chemie, Biochemie und Isotopenforschung der
Universität Stuttgart, Pfaffenwaldring 55, D-7000 Stuttgart 80

Summary: Aldol condensation of (2R,4E)-2-methyl-4-hexenal 4 with the lithium enolate of N,N,O-tris(trimethylsilyl)glycine produces exclusively the two erythro-isomers 5 and 6 (75:25), which are separated by medium pressure chromatography. Each diastereomer is transformed separately with complete Walden inversion into the oxazolines 9 and 10, which are N-methylated, reduced and hydrolyzed to give MeBmt 15 and its diastereomer 16, respectively.

The immunosuppressive cyclopeptide cyclosporine contains N-methylvaline, N-methylleucine, and MeBmt als "non-protein" amino acids. In the course of his synthesis of cyclosporine, R.M.Wenger prepared MeBmt in 24 steps starting from tartaric acid². A few month ago, D.A.Evans described the preparation of MeBmt by means of an aldol condensation of a chiral isothiocyanoacetyl-oxazolidinone with chiral (2R,4E)-2-methyl-4-hexenal 4 under conditions of "double stereodifferentiation" using the tin triflate technique³. A recent synthesis by D.H.Rich utilized Sharpless' asymmetric epoxidation of (2E,5E)-heptadien-1-ol but required more steps than Evans' and our route and gave a product of only 94% ee through crystallization of a key intermediate⁴.

In this communications we report a further total synthesis of MeBmt. In the key step, the two asymmetric centers at the 2- and 3-positions are formed from the chiral aldehyde 4 by exploitation of "Cram" control and the known erythro-selectivity of trisilylated glycines in aldol condensations⁵. Although the high diastereoselectivity of Evans' synthesis is not achieved, the starting material is more readily accessible and the reaction is considerably more simple to perform. The method requires only one chromatographic separation and leads directly to an N,O-protected derivative 12a,b that is suitable for use in further peptide syntheses. This sequence avoids the incomplete⁴ epimerization of an oxazolidinone derivative used in the other syntheses^{2,3,4}.



Scheme 2

a) 2 eq LDA/THF/2 eq $(Me_3Si)_2N-CH_2-COOSiMe_3$ /1 h, $-78^\circ C \rightarrow 0^\circ C$, 12 h//HCl/EtOH/pH 3/5 min//pH 7. b) dioxane/ H_2O = 1:1/2.5 eq $NaHCO_3$ /2.1 eq $PhCOCl$ /4 h/r.t.//evaporation to dryness/EtOAc extraction; c) MeOH/ CH_2NH_2 ($\underline{4} \rightarrow \underline{7,8}$, 68% yield); d) $\underline{7}$, 0.1 M in CH_2Cl_2 /10 eq $SOCl_2$ /0°/10 h, (96% yield); e) CH_2Cl_2 /MeOSO₂CF₃/4 h/r.t. (quantitative)//EtOH abs./1 eq $NaBH_4$ /1h/r.t.//phosphate buffer pH 8//EtOH evaporation//Et₂O extraction ($\underline{11a,b}$, 95% yield); f) 0.1 M in MeOH/1.05 eq 1N NaOH/4 h/r.t.; g) MeOH/1 N HCl/pH 5/30 min/r.t. ($\underline{11a,b} \rightarrow \underline{15}$, 98% yield)

Acknowledgement: W. Siegel greatly appreciates a grant from the Land Baden-Württemberg.

Notes and references

- 1 Amino acids and peptides, 62. Part 60: U.Schmidt, D.Weller, Tetrahedron Lett. 27, 3495 (1986).
- 2 R.M.Wenger, Helv.Chim.Acta 66, 2308 (1983).
- 3 D.A.Evans, A.E.Weber, J.Am.Chem.Soc. 108, 6757 (1986).
- 4 D.H.Rich, R.D.Tung, Tetrahedron Lett. 28, 1139 (1987).
- 5 A.Shanzer, L.Somekh, D.Butina, J.Org.Chem. 44, 3967 (1979).
- 6 G.Helmchen, G.Grotmaier, R.Schmieder, A.Selim, Angew.Chem. 93, 209 (1981); Angew.Chem.Int.Ed.Engl. 20, 207 (1981).
- 7 A simple synthesis of racemic (2R/S,4E)-2-methyl-4-hexenoic acid by Claisen rearrangement of 1-buten-3-yl-propanoat and subsequent separation of its diastereomeric threonine benzylester amides will be reported elsewhere (A.Holder, Stuttgart 1986).
- 8 D.Swern, A.J.Mancuso, S.-L.Huang, J.Org.Chem. 43, 2480 (1978).
- 9 K.Rühlmann, G.Kuhrt, Angew.Chem. 80, 797 (1968); Angew.Chem.Int.Ed.Engl. 7, 809 (1968).
- 10 S.Futagawa, T.Inui, T.Shiba, Bull.Soc.Chem.Jpn. 46, 3308 (1973).
- 11 ¹HNMR data (300 MHz, CDCl₃) if not otherwise indicated.
 3: δ = 0.82 (s,3H), 0.83 (s,3H), 1.03 (s,3H), 1.07-1.15 (m,1H), 1.31 (d, 3H, J=7Hz), 1.7-1.76 (m,1H), 1.83-1.85 (m,1H), 2.07 (s,3H), 2.21-2.3 (m,2H), 2.3 (s,3H), 2.51-2.64 (m,2H), 3.95 (d,2H, J=6.6Hz), 4.20 (dd,1H, J=3.3, 8.7Hz), 5.38 (d,1H, J=8.7Hz), 5.79-5.84 (m,2H), 5.96 (br s,1H), 6.85 (br s, 1H), 6.97 (br s,1H), 7.28-7.4 (m,3H), 7.49-7.55 (m,1H). [α]_D²⁰ = +1.79° (c = 11.8, CH₂Cl₂).
 7: δ = 0.98 (d,3H, J=6.7Hz), 1.65 (dd,3H, J=0.8, 5.8Hz), 1.66-1.76 (m,1H), 1.89-2.02 (m,1H), 2.17-2.24 (m,1H), 3.38 (br,1H), 3.67-3.8 (1H), 3.75 (s, 3H), 4.97 (dd, 1H, J=4.1, 8.1Hz), 5.34-5.51 (m,2H), 7.26 (d,1H, J=8.1Hz), 7.36-7.51 (m,3H), 7.78-7.82 (m,2H). [α]_D²⁰ = +32.9° (c = 0.9, CH₂Cl₂).
 8: δ = 0.99 (d,3H, J=6.7Hz), 1.65 (d,3H, J=4.9Hz), 1.67-1.76 (m,1H), 1.91-2.03 (m,1H), 2.32-2.39 (m,1H), 3.24 (br,1H), 3.67 (dd,1H, J=2.8, 9.3Hz), 3.79 (s,3H), 4.97 (dd,1H, J=2.8, 7.5Hz), 5.36-5.54 (m,2H), 7.27 (d,1H, J=7.5Hz), 7.31-7.54 (m,3H), 7.8-7.84 (m,2H). [α]_D²⁰ = -37.8° (c = 1, CH₂Cl₂).
 9: δ = 0.93 (d,3H, J=5.6Hz), 1.66 (dd,3H, J=0.9, 5.8Hz), 1.86-2.04 (m,2H), 2.23-2.3 (m,1H), 3.8 (s,3H), 4.59 (d,1H, J=7.1Hz), 4.75 (dd,1H, J=6.5, 7.1Hz), 5.38-5.53 (m,2H), 7.37-7.52 (m,3H), 7.97-8.01 (m,2H). [α]_D²⁰ = +110.4° (c = 2.89, CH₂Cl₂).
 10: δ = 0.97 (d,3H, J=6.7Hz), 1.65 (dd,3H, J=1.0, 5.8Hz), 1.74-1.89 (m,1H), 1.91-2.01 (m,1H), 2.15-2.25 (m,1H), 3.79 (s,3H), 4.60 (d,1H, J=7.1Hz), 4.81 (dd,1H, J=5.3, 7.1Hz), 7.37-7.52 (m,3H), 7.96-8.01 (m,2H). [α]_D²⁰ = -142.5° (c = 0.92, CH₂Cl₂).
 16 (D₂O): δ = 0.96 (d,3H, J=6.6Hz), 1.67 (d,3H, J=6.1Hz), 1.68-1.78 (m, 1H), 1.96-2.14 (m,2H), 2.75 (s,3H), 3.58 (d,1H, J=8.6Hz), 3.82 (dd,1H, J=3.3, 8.6Hz), 5.42-5.65 (m,2H). [α]_D²⁰ = +9.2° (c = 0.56, pH 7 phosphate buffer).

(Received in Germany 31 March 1987)